Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer
© Shibata et al; licensee BioMed Central Ltd. 2010
Received: 26 July 2010
Accepted: 19 October 2010
Published: 19 October 2010
The effects of raloxifene, a novel selective estrogen receptor modulator, were studied in a mouse metastatic mammary cancer model expressing cytoplasmic ERα.
Mammary tumors, induced by inoculation of syngeneic BALB/c mice with BJMC3879luc2 cells, were subsequently treated with raloxifene at 0, 18 and 27 mg/kg/day using mini-osmotic pumps.
In vitro study demonstrated that the ERα in BJMC3879luc2 cells was smaller (between 50 and 64 kDa) than the normal-sized ERα (66 kDa) and showed cytoplasmic localization. A statistically significant but weak estradiol response was observed in this cell line. When BJMC3879luc2 tumors were implanted into mice, the ERα mRNA levels were significantly higher in females than in males. In vitro studies showed that raloxifene induced mitochondria-mediated apoptosis and cell-cycle arrest in the G1-phase and a decrease in the cell population in the S-phase. In animal experiments, tumor volumes were significantly suppressed in the raloxifene-treated groups. The multiplicity of lymph node metastasis was significantly decreased in the 27 mg/kg group. Levels of apoptosis were significantly increased in the raloxifene-treated groups, whereas the levels of DNA synthesis were significantly decreased in these groups. No differences in microvessel density in tumors were observed between the control and raloxifene-treated groups. The numbers of dilated lymphatic vessels containing intraluminal tumor cells were significantly reduced in mammary tumors in the raloxifene-treated groups. The levels of ERα mRNA in mammary tumors tended to be decreased in the raloxifene-treated groups.
These results suggest that the antimetastatic activity of raloxifene in mammary cancer expressing cytoplasmic ERα may be a crucial finding with clinical applications and that raloxifene may be useful as an adjuvant therapy and for the chemoprevention of breast cancer development.
The selective estrogen receptor modulators (SERMs) exhibit specific estrogen-receptor (ER) agonistic and antagonistic activity by binding to ERα and/or β. Of the SERMs, tamoxifen and raloxifene differ from estrogens in that they exert both agonistic and antagonistic properties. Tamoxifen acts as an antagonist in the breast and an agonist in the bone and uterus. Therefore, tamoxifen is used clinically as a therapeutic agent to treat ER-positive breast cancer. Although tamoxifen prevents ER-positive breast cancers , it increases the incidence of endometrial cancer [2, 3]. Raloxifene has antiestrogenic effects on the breast and bone, but it does not have an estrogenic effect on the uterus. These SERMs have different biological actions because raloxifene recruits a co-repressor in endometrial carcinoma cells, whereas tamoxifen induces a co-activator . In fact, raloxifene inhibits carcinogen-induced mammary carcinoma [5–7] and colon carcinoma  in animal models.
The Study of Tamoxifen and Raloxifene (STAR) trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer, and there were less cases of endometrial cancer with raloxifene than with tamoxifen . Results of other clinical trials of raloxifene, such as the Multiple Outcomes of Raloxifene Evaluation (MORE) , Continuing Outcomes Relevant to Evista (CORE)  and the Raloxifene Use for The Heart (RUTH)  trials, showed that raloxifene reduces the risk of invasive ER-positive breast cancer in postmenopausal women. As compared with tamoxifen, raloxifene appears to have fewer serious side effects, including endometrial cancer, venous thrombosis and cataracts, without compromising the breast cancer chemoprevention strategy .
Breast cancer is the most common malignancy in women worldwide and is one of the most lethal carcinomas. In Japan, the incidence of breast cancer is continuously increasing and the disease now ranks fifth as a cause of female mortality; the number of breast cancer deaths in Japan increased 2.6-fold between 1975 and 1998 . The lethality of breast cancer is largely due to metastasis; the most common sites are lung, lymph nodes, liver, and bone. Effective and less toxic chemopreventive agents are needed to delay the progression of breast cancer and prolong life.
Here, we investigated the chemopreventive ability of raloxifene, especially its antimetastatic ability, in a mouse metastatic mammary cancer model expressing cytoplasmic ERα. This mammary cancer model has a p53 mutation that shows a metastatic spectrum similar to that seen in human breast cancers [15–17]. In addition, we studied the apoptosis pathway, DNA synthesis, and cell cycle in metastatic mouse mammary carcinoma cells treated with raloxifene in vitro.
Raloxifene hydrochloride was purchased from Sigma Co. (St. Louis, MO, USA). For in vitro use, raloxifene was dissolved in dimethylsulfoxide (DMSO), and aliquots of 20 mM stock solution were stored at -20°C.
Cell line and animals
The BJMC3879luc2 mammary carcinoma cell line  was generated by stable transfection of luc2 (an improved firefly luciferase gene) into parent cell line BJMC3879. The mammary tumors arising from BJMC3879 cell implantation had a high propensity for metastasis into the lymph nodes and lungs [15–17], a trait retained through culture. BJMC3879luc2 cells were maintained in RPMI 1640 medium containing 10% fetal bovine serum with streptomycin/penicillin in an incubator under 5% CO2.
Thirty female 6-week-old BALB/c mice were used in this study (Japan SLC, Hamamatsu, Japan). The animals were housed five per plastic cage on wood chip bedding with free access to water and food under controlled temperature (21 ± 2°C), humidity (50 ± 10%), and lighting (12-12 h light-dark cycle). All animals were held for a 1-week acclimatization period before study commencement. Mice were treated in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals in Osaka Medical College, the Japanese Government Animal Protection and Management Law (No. 105) and the Japanese Government Notification on Feeding and Safekeeping of Animals (No. 6).
Estrogen receptor expression
BJMC3879luc2 cells were grown in 2-well chamber slides and fixed in 4% formaldehyde solution in phosphate buffer. Immunofluorescence staining was performed with anti-ERα rabbit polyclonal antibody (clone MC-20; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Total protein was extracted from whole cell lysates of BJMC3879luc2 cells. Total protein (40 μg) was electrophoretically separated in 14% Tris-glycine gels under reducing conditions and transferred to nitrocellulose membranes. The membrane was incubated with anti-ERα (Santa Cruz Biotechnology) or anti-ERβ (Affinity Bioreagents, Golden, CO, USA) rabbit polyclonal antibodies, followed by secondary antibodies conjugated to HRP. Then, the bound antibody was visualized with enhanced chemiluminescence reagent (Perkin Elmer Life Sciences Inc., Boston, MA, USA). Blots were visualized using a LAS-3000 image analyzer (Fujifilm, Co., Tokyo, Japan). Anti-Bid and anti-actin goat polyclonal antibodies (Santa Cruz Biotechnology) were used as primary antibodies.
ERα expression of BJMC3879luc2-implanted tumors in females and males
BJMC3879luc2 cells (5 × 106 cells/0.3 ml in PBS) were inoculated subcutaneously into the right inguinal mammary fat pad of 10 BALB/c mice (5 females and 5 males). From two to four weeks after the inoculation, the mammary tumors were measured with digital calipers. The tumor volumes were calculated with the following formula: maximum diameter × (minimum diameter)2 × 0.4 . Four weeks after inoculation, mammary tumors were immediately excised under isoflurane anesthesia. Total RNA was extracted, and transcriptional levels of ERα were measured in mammary tumors using real-time reverse transcriptase (RT)-PCR (see "ERα expression in mammary tumors" for details).
BJMC3879luc2 cells were grown in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum and 2 mM L-glutamine under an atmosphere of 95% air and 5% CO2 at 37°C. BJMC3879luc2 cells were plated onto 96-well plates (1 × 104 cells/well) 1 day before raloxifene treatment. They were subsequently incubated for 24 h with culture medium containing vehicle (DMSO) alone or with medium containing raloxifene at different concentrations up to 80 μM. Cell viability was determined using a CellTiter-Blue Cell Viability Assay (Promega Co., Madison, WI, USA). In addition, to examine the response to estrogen in BJMC3879luc2 cells, one week before the experiment, the medium was changed to a phenol red-free form of RPMI-1640 containing charcoal-stripped fetal bovine serum (steroid-free medium). The cells were seeded at 5 × 104 cells/well in the culture medium (steroid-free and phenol red-free). After overnight culture, the cells were exposed to 17-β estradiol (E2) at final concentrations of 10-12 to 10-4 M (1 pmole to 100 μmole) for 24 h, and then cell viability was determined as described above.
TUNEL assay, caspase activity and DNA synthesis
BJMC3879luc2 cells were grown in 2-well chamber slides and treated with 20 μM raloxifene for 48 h. Then, the cells were fixed in 4% formaldehyde solution in phosphate buffer, and terminal deoxynucleotidyl transferase-mediated dUTP-FITC nick end-labeling (TUNEL) staining was performed according to the manufacturer's protocol (Wako Pure Chemical Industries, Osaka, Japan).
BJMC3879luc2 cells were plated onto 96-well plates (1 × 104 cells/well) 1 day before raloxifene treatment. Cells were treated with 20 μM raloxifene or vehicle alone for 48 and 72 h, and then cell viability was measured using a CellTiter-Blue Cell Viability Assay (Promega). The activities of caspase-8, caspase-9 and caspase-3 were measured using a luminescent assay kit (Promega). Caspase activity was measured in terms of the luminescent signal produced by caspase cleavage of the corresponding substrate using a Luminoskan Ascent device (Thermo Electron Co., Helsinki, Finland). Caspase activity levels were corrected by the corresponding cell viabilities. In addition, cells from the cultures were incubated for 1 h in medium containing 50 μM 5-bromo-2'-deoxyuridine (BrdU), and DNA synthesis of the cells was measured by BrdU incorporation (Cell Proliferation on ELISA, BrdU Chemiluminescence; Roche Diagnostics, GmbH, Mannheim, Germany). Data were also corrected by the corresponding cell viabilities.
Release of cytochrome c
After incubation in culture medium with or without 20 μM raloxifene for 48 h, both floating and attached cells were harvested, rinsed once in PBS, re-suspended in cell lysis buffer, incubated for 1 h at room temperature, and centrifuged at 1000 × g for 15 min. The resultant supernatant was diluted at least 5-fold. Supernatants containing the cytosolic fraction were collected separately, and the protein concentrations were determined. To determine the cytochrome c release into the cytosol, cytochrome c was measured using a cytochrome c kit (R&D Systems, Inc, Minneapolis, MN, USA).
Caspase inhibitor experiment
Cells were treated with 10 μM and 100 μM of the following caspase inhibitors for 48 h: z-VAD-fmk against broad-spectrum caspases, Ac-DNLD-CHO against caspase-3, z-IETD-fmk against caspase-8 and z-LEHD-fmk against caspase-9. The caspase inhibitors, with the exception of caspase-3 inhibitor (Peptide Institute, Inc., Osaka, Japan), were purchased from MBL Inc. (Nagoya, Japan). Although DEVD has been generally used as a caspase-3 inhibitor, this sequence has been reported to be non-specific to caspase-3; therefore, Ac-DNLD-CHO was used in the present experiment [20, 21]. Two hours after treatment with caspase inhibitors, cells were exposed to 20 μM raloxifene. Cell viability was measured using a fluorescent assay kit (CellTiter-Blue Cell Viability Assay, Promega), and then the activities of caspase-3, caspase-8 and caspase-9 were measured using a luminescent assay kit (Promega). The caspase activity data was then adjusted to account for the corresponding cell viability as previously reported .
Flow cytometric analysis was conducted on trypsinized BJMC3879luc2 cell suspensions that were harvested after a 48-h treatment with 20 μM raloxifene and fixed in cold 70% ethanol. The cells were stained with a 50 μg/ml propidium iodide solution containing 100 μg/ml RNase A for 30 min at 37°C and then placed on ice just prior to flow cytometric analysis (EPICS Elite ESP; Coulter Co., Miami, FL, USA). The percentage of cells in each phase of the cell cycle was determined using a Multicycle Cell Cycle Analysis program (Coulter Co.).
In vivo study of raloxifene in a metastatic mammary cancer model
Two dosages of raloxifene for mice (27 mg/kg and 18 mg/kg) were selected based on the results of other studies . Raloxifene was continuously administered via subcutaneously implanted mini-osmotic pumps (Alzet model 2002, Durect Co., Cupertino, CA, USA) that were calibrated to release 0.5 μl of solution per hour. Raloxifene solutions (47.5 mg/ml and 31.7 mg/ml) in DMSO and 100% ethanol (1:3, v/v) were prepared. Since the pumps were calibrated to release for 14 days, they were replaced every other week.
BJMC3879luc2 cells (5 × 106 cells/0.3 ml in PBS) were subcutaneously inoculated into the right inguinal mammary fat pad of 30 female BALB/c mice. Two weeks later, when tumors had reached approximately 0.6 cm in diameter, mini-osmotic pumps were used to administer 0, 18 or 27 mg/kg raloxifene for 6 weeks. Individual body weights were recorded weekly. Each mammary tumor was also measured weekly using digital calipers, and tumor volumes were calculated according to the formula of maximum diameter × (minimum diameter)2 × 0.4 . All animals received 50 mg/kg BrdU (Sigma Co.) i.p. at 1 h prior to sacrifice. All surviving mice were euthanized with isoflurane anesthesia at week 6.
Bioluminescence imaging in vivo
At week 6, five mice in each group were anesthetized by isoflurane inhalation with an SBH Scientific anesthesia system (SBH Designs Inc., Ontario, Canada). Each anesthetized mouse received an intraperitoneal injection of 3 mg of D-luciferin potassium salts (Wako Pure Chemical Industries). Bioluminescence imaging with a Photon Imager (Biospace Lab, Paris, France) was performed. The bioluminescent signals received during the 6-min acquisition time were quantified using Photovision software (Biospace Lab).
At necropsy, tumors and lymph nodes were removed, fixed in 10% formaldehyde solution in phosphate buffer and processed through to paraffin embedding. The lymph nodes from the axillary and femoral regions were routinely removed, along with lymph nodes that appeared abnormal. In several cases, the uterus was also excised and preserved in fixative solution. Lungs were inflated with formaldehyde solution prior to excision and immersion in fixative; the individual lobes were subsequently removed from the bronchial tree and examined for metastatic foci and similarly processed through to paraffin embedding. All paraffin-embedded tissues were cut into 4-μm-thick sections. Sequential sections were stained with hematoxylin and eosin for histopathological examination or remained unstained for immunohistochemical analysis.
The labeled streptavidin-biotin (LSAB) method (Dako, Glostrup, Denmark) was used for p53 immunohistochemistry. Unstained sections were immersed in distilled water and heated for antigen retrieval prior to incubation with a p53 mouse monoclonal antibody (Clone Pab240, Santa Cruz Biotechnology) that reacts to the mutant protein in fixed specimens.
Apoptosis and caspase in mammary tumors
For the quantitative analyses of cell death, sections from paraffin-embedded tumors were assayed using the TUNEL method in conjunction with an apoptosis in situ detection kit (Wako Pure Chemical Industries) with minor modifications to the manufacturer's protocol. TUNEL-positive cells (mainly regarded as apoptotic cells) were counted in viable regions peripheral to areas of necrosis in tumor sections. The slides were scanned at low-power (×100) magnification to identify those areas having the highest number of TUNEL-positive cells. Four areas neighboring the highest area of TUNEL-positive cells were then selected and counted at higher (×200-400) magnification. The numbers of TUNEL-positive cells were expressed as numbers per cm2.
Active caspase expression of the mammary tumor tissues was immunohistochemically detected using anti-cleaved caspase-3 and cleaved caspase-9 rabbit polyclonal antibodies (Cell Signaling Technology, Danvers, MA, USA). Immunohistochemistry was conducted using the LSAB method, and CSA II amplification (Dako) was additionally applied to detect cleaved caspase-9.
DNA synthesis in mammary tumors
The tumors from five animals from each treatment group were subsequently evaluated for DNA synthesis rates as inferred by BrdU incorporation. DNA was denatured in situ by incubating unstained paraffin-embedded tissue sections in 4 N HCl solution for 20 min at 37°C. The incorporated BrdU was visualized after exposure to an anti-BrdU mouse monoclonal antibody (Clone Bu20a, Dako). The numbers of BrdU-positive S-phase cells per 250 mm2 were counted in four random high-power (×400) fields of viable tissue, and the BrdU labeling indices were expressed as numbers per cm2.
Lymphatic and blood microvascular densities in mammary tumors
To quantitatively assess lymphatic and blood microvessel density in the primary mammary carcinomas, immunohistochemistry based on the LSAB method (Dako) was performed. A hamster anti-podoplanin monoclonal antibody (AngioBio Co., Del Mar, CA, USA) against a lymphatic endothelium marker and a rabbit polyclonal antibody against CD31 (Lab Vision Co., Fremont, CA, USA), a specific marker for blood vessel endothelium, were used. The number of podoplanin-positive lymphatic vessels containing intraluminal tumor cells was also counted. In addition, the number of CD31-positive blood microvessels was counted as previously described . Briefly, the slides were scanned at low-power (×100) magnification to identify those areas having the highest number of vessels. The five areas of highest microvascular density were then selected and counted at higher (×200-400) magnification.
ERα expression in mammary tumors
Immunohistochemical staining for ERα (anti-ERα rabbit polyclonal antibody, Santa Cruz Biotechnology) was performed using the LSAB method in combination with a CSA II amplification kit (Dako). In addition, the levels of ERα mRNA in mammary tumor tissues were also measured using a real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Total RNA was isolated from two 4-μm sections of each paraffin-embedded tumor using an RNeasy FFPE kit (Qiagen, GmbH, Hilden, Germany), and cDNAs were synthesized according to the manufacturer's instructions (Roche Diagnostics). cDNAs were then amplified using a LightCycler and LightCycler FastStart DNA Master SYBR Green I according to the manufacturer's instructions (Roche Diagnostics). The primer sequences for mouse ERα were 5'-AAAGCTGGCCTGACTCTG-3' and 5'-GATGCTCCATGCCTTTGT-3'. The primer sequences for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as an internal control, were 5'-TGGCCTTCCGTGTTCCTACC-3' and 5'-AGCCCAAGATGCCCTTCAGT-3'. The primer sequences of ERα and GAPDH were determined based on data from the GenBank in the National Institutes of Health, USA. The product length was 100 bp for ERα and 135 bp for GAPDH. The levels of ERα mRNA were calculated using a 2-ΔΔCt method . The method is based on the fact that the difference in threshold cycles (ΔCt) between the gene of interest (ERα) and housekeeping gene GAPDH is proportional to the relative expression level of the gene of interest.
Significant differences in the quantitative data between the groups were analyzed using the Student's t-test via the method of Welch, which provides for insufficient homogeneity of variance. The differences in metastatic incidence were examined by Fisher's exact probability test, with P < 0.05 or P < 0.01 considered to represent a statistically significant difference.
ER expression of mammary carcinoma cells
In vitro raloxifene study
Significantly elevated activities of caspase-3, caspase-8 and caspase-9 were observed in BJMC3879luc2 cells treated with raloxifene for 24 h (Figure 2B) and 48 h (data not shown), as compared to the respective controls. However, the activities of caspase-12 did not show significant differences between control cells and raloxifene-treated cells (Figure 2B).
Release of cytochrome c
Cytochrome c protein levels in cytosolic fractions were significantly elevated in cells treated with raloxifene for 48 h (Figure 2C). These findings strongly suggest the engagement of the mitochondria-mediated apoptotic pathway.
Since caspase-8 activities were elevated, we examined whether caspase-8-Bid cleavage via the mitochondrial pathway occurred by performing western blots for Bid. Full-length Bid (22 kDa) was detected in control cells and in cells treated with raloxifene for 48 h (Figure 2D). No cleaved Bid was found.
Caspase inhibitor experiment
To determine whether caspase activation is necessary to induce raloxifene-induced apoptosis, a caspase inhibitor experiment was conducted. The recovery of cell viability occurred in cells treated with all caspase inhibitors and raloxifene as compared with raloxifene alone for 48 h (Figure 2E).
Cell cycle and DNA synthesis
As measured by flow cytometry, 48 h exposure to 20 μM raloxifene induced a significant elevation in the numbers of cells in the G1-phase as compared with control cells (Figure 2F). There was also a significant reduction in the S-phase population in raloxifene-treated cell suspensions (Figure 2F). DNA synthesis in BJMC3879luc2 cells treated with raloxifene for 48 h, as assessed by BrdU incorporation, was significantly decreased (Figure 2G).
In vivo raloxifene study
Body weights and mammary tumor growth
Tumor volumes are presented in Figure 3B. Tumor growth, as inferred by computed volume, was significantly inhibited in the 18 and 27 mg/kg groups from week 3 to the end of the experiment when compared with controls. By the end of the experiment, the average tumor volume in control animals was 1500 ± 183 mm3, while the average tumor volume of mice that received raloxifene was 729 ± 277 mm3 (18 mg/kg) and 654 ± 161 mm3 (27 mg/kg).
Metastasis of mammary carcinomas
Histopathologically, the mammary carcinomas induced by BJMC3879luc2 cell inoculation proved to be moderately differentiated adenocarcinomas (Figure 4D) that contained mutated p53 as inferred by immunohistochemistry (Figure 4E).
Lymph node metastasis
Representative lymph node metastases are shown in Figures 4F and 4G. Lymph node metastasis occurred in all mice independent of groups. However, the number of metastasis-positive lymph nodes per mouse was significantly decreased in the 27 mg/kg group as compared to the control group (Figure 3C).
Lung metastasis occurred in all mice. The number of lung metastatic foci (>200 μm) per mouse tended to decreases in the raloxifene-treated groups, although the decrease was not statistically significant (Figure 3D). However, the metastatic foci tended to be smaller in the raloxifene-treated groups (Figure 4I) than in the control animals (Figure 4H). In addition, there was no difference in the uterine endometrium of the control mice and the raloxifene-treated mice (Figure 4J, K).
Apoptosis and DNA synthesis in mammary cancers
DNA synthesis levels in mammary carcinomas of raloxifene-treated mice (18 and 27 mg/kg), as inferred by BrdU labeling indices, are shown in Figure 5B. Levels of DNA synthesis in tumors were significantly decreased in the 18 and 27 mg/kg groups (Figure 5B and 6G, H).
Blood microvascular density and lymphatic vessels in mammary cancers
Microvessel density, as determined by immunohistochemical analysis with the blood vessel endothelial cell marker CD31, showed no statistically significant difference between control mice and raloxifene-treated mice (Figure 5C).
The lymphatic vessels in mammary tumors were stained with anti-podoplanin antibody, as demonstrated in Figures 6I and 6J. There were tumor cells within the lumina of dilated lymphatic vessels of tumors in both control (Figure 6I) and raloxifene-treated animals (Figure 6J). However, the number of dilated lymphatic vessels containing intraluminal tumor cells (arrows in Figure 6I, J) was significantly reduced in mammary tumors of mice given 18 and 27 mg/kg of raloxifene (Figure 5D), indicating a reduction in the number of tumor cells migrating into the lymphatic vessels of tumor tissues.
ERα expression of mammary carcinoma
Immunohistochemically, adjacent normal mammary glands in the mammary carcinomas showed nuclear expression of ERα in the control mice (Figure 6K), while the ERα expression level of normal mammary glands in the raloxifene-treated mice tended to be decreased (Figure 6L). In mammary carcinoma tissues, the scattered expression of ERα was observed in the cytoplasm of both control mice (Figure 6M) and raloxifene-treated mice (Figure 6N), and the expression level tended to decrease in the raloxifene-treated mice. In the quantitative analysis, levels of ERα mRNA in mammary carcinoma tissues tended to decrease in mice treated with raloxifene as compared to the control mice, but the decrease was not statistically significant (Figure 5E).
The present study showed that raloxifene inhibited tumor growth and multiplicity of metastasis to lymph nodes in a mouse immunocompetent metastatic mammary carcinoma model expressing cytoplasmic ERα. In addition, tumor tissues from the raloxifene-treated mice showed elevation of apoptotic cell death, suppression of DNA synthesis and inhibition of lymphatic vessels containing intraluminal cancer cells.
The present in vitro studies showed that the ERα expressed in the mammary carcinoma BJMC3879luc2 cells used in this study was between 50 and 64 kDa, which is smaller than the 66-kDa size of normal ERα, and it showed a cytoplasmic location. Cell proliferation of BJMC3879 cells expressing the smaller molecular weight ERα was significantly increased, but only by 7%, when added to 10 nM estrogen. When BJMC3879luc2 cells were implanted into mice, the ERα mRNA levels in the resultant tumors were significantly higher in female mice as compared to the male mice. Thus, although the ERα in the present study might be functional but weak, further investigation is necessary to elucidate this point. Recently, a truncated variant of 36-kDa ERα has been identified . This subtype, which is predominantly localized to the cytoplasm and plasma membrane, responds to estrogen and mediates a nongenomic signaling pathway. Although this 36-kDa variant of ERα is apparently different from the present ERα, they share similarities in regard to localization and estrogen response.
The results of STAR , MORE , CORE  and RUTH  clinical trials show that raloxifene does not reduce the risk of ER-negative invasive breast cancer. Therefore, the fact that raloxifene exerted antimetastatic effects on mammary cancer expressing the cytoplasmic form of ERα may be an important finding with clinical applications. The question was raised as to why raloxifene exerted antitumor effects on mammary tumors that expressed the cytoplasmically located ERα in the present study. ER lacks known functional motifs that would allow for nongenomic mechanisms of estrogen action . Raloxifene acts on both nuclear ERα and cytoplasmic ERα (nongenomic action) . In this case, raloxifene does not target the estrogen response element; rather, it targets the raloxifene response element . It was previously reported that estrogen activates cell proliferation in even ER-negative human breast cancer cells MDA-MB231 via GPR30, a member of the G protein-coupled receptor superfamily . Thus, raloxifene can act by nongenomic mechanisms independent of ER, indicating the complexity and variety of SERMs. The biological effects of raloxifene decrease the ER levels [8, 31]. In fact, in the present in vivo study, the mRNA levels of the truncated ERα in mammary tumors of raloxifene-treated mice showed a tendency to be decreased as compared to the levels in control mice. It is possible that raloxifene acts on the present mammary cancer model. In addition, ERα and β have been previously localized to mitochondria in various tissues [32, 33]. In the present study, immunohistochemical localization of the truncated ERα revealed scattered expression in the cytoplasm, suggesting mitochondrial localization.
The present study demonstrated that raloxifene significantly induced apoptosis in murine mammary carcinoma cells both in vitro and in vivo. There are two pathways currently proposed to play major roles in regulating apoptosis in mammalian cells: a pathway mediated by death receptor (extrinsic pathway; execution by caspase-8) and a pathway mediated by mitochondria (intrinsic pathway; execution by caspase-9) . Caspase-3 is a final executor of apoptosis. Many of the apoptosis signals are transduced to the mitochondria and decrease the mitochondrial membrane potential, which leads to the release of cytochrome c from the mitochondrial lumen into the cytoplasm. The released cytochrome c binds to the apoptosis protease-activating factor-1 (Apaf-1), and this complex activates caspase-9. Caspase-8 also has a cross-talk pathway to the mitochondria pathway through the cleavage of Bid .
In the present in vitro study, increases in caspase activities (caspase-3, -8 and -9) and cytosolic cytochrome c levels were found in mammary carcinoma cells treated with raloxifene, suggesting that raloxifene at least induced mitochondria-mediated apoptosis. Indeed, mammary cancer tissues of mice treated with raloxifene showed strong expression of active caspase-3 and -9 (cleaved forms), demonstrating that mitochondria-mediated apoptosis also occurred in vivo. All caspase inhibitors involving a caspase-8 inhibitor completely rescued raloxifene-induced cell death. However, since Bid cleavage was not observed, cross-talk between caspase-8 and Bid may not be involved. The question was raised as to why caspase-8 activity increased. Caspase-8 participates in ERK activation, and this regulation is attributed to the Death Effector Domains (DED) of caspase-8 . Furthermore, a direct association between ERK and a DED-containing fragment of caspase-8, and co-transport of an ERK-caspase-8-DED complex to the nucleus during apoptosis has been reported . The caspase-8-ERK pathway may also play a role in raloxifene-induced apoptosis. Further investigation is required to elucidate this point. In addition, caspase-12 mediates the pathway for cell death induced by endoplasmic reticulum stress in mice . In the present study, since no elevation in caspase-12 activity was seen, the raloxifene-induced apoptosis may not have involved endoplasmic reticulum stress.
In animal carcinogenesis models, raloxifene at 20 mg/kg/day inhibits the tumor growth of 7, 12-dimethylbenzanthracene-induced mammary carcinomas in rats . In mice, orally administered raloxifene (1.5 mg/mouse) reduces the tumor growth of mammary and endometrial cancer . On the assumption that mouse body weights are 30 g, the dosage of raloxifene is estimated to be 50 mg/kg/day in mice. In carcinogenicity studies in mice and rats, raloxifene (8.7~225 mg/kg/day in mice; 10.4~259 mg/kg/day in rats) is not carcinogenic (company data from Eli Lilly Pharmaceuticals, Indianapolis, IN, USA). Although the clinical dosages of raloxifene in trials are 60 mg or 120 mg/day, a much higher dose of 600 mg/day (estimated as 10 mg/kg/day on the assumption that body weight is 60 kg) has also been used in clinical studies without adverse side effects [38, 39]. Therefore, the doses of raloxifene used in the present mouse study (18 and 27 mg/kg/day) are not extremely high, and the dosage levels are considered to be near the clinical dose. However, low doses of raloxifene also exert antitumorigenic effects in animal cancer models .
Cancer cells metastasize to distal sites via the lymphatic system and the vascular system. The lymphatic capillaries present in tissues and tumors provide entrance into the lymphatics, allowing cancer cell migration to the lymph nodes. In the present study, it was demonstrated that the multiplicity of lymph node metastases was decreased in raloxifene-treated mice. This phenomenon was supported by a significant decrease in the number of lymphatic vessels with tumor cells in their lumina in the raloxifene-treated groups. This finding indicates that raloxifene may have an inhibitory effect on migration into lymphatic vessels. In fact, raloxifene has been reported to inhibit estrogen-induced cell migration and invasion through a non-nuclear signaling cascade involving G proteins and the RhoA-associated kinase . It was also reported that raloxifene decreases levels of cyclooxygenase-2 and inducible nitric oxide synthase in carrageenan-induced inflammation of rats . This mechanism could possibly be involved in the antitumorigenic effects of raloxifene.
Neovascularization is also a key process in the growth of solid tumors, and the growth of both primary tumors and metastases is thus angiogenesis-dependent . However, in the present study, microvessel density in tumors was similar between the control and raloxifene-treated groups, indicating that raloxifene may not have anti-angiogenic action. However, the microvessel density in the 27 mg/kg raloxifene group was slightly increased. Since raloxifene induces cell proliferation and up-regulation of telomerase activity in human umbilical vein endothelial cells , this effect might be involved in the present study. However, since raloxifene did not inhibit angiogenesis in tumors in the present study, lung metastasis may not have been strongly inhibited.
The present experiments suggest that raloxifene-induced apoptosis in BJMC3879Luc2 cells having a p53 mutation occurs through a p53-independent mechanism. Since 50% of human cancers have p53 mutations , the fact that the raloxifene induces a p53-independent apoptotic response in cancer cells having a p53 mutation may be highly relevant to inhibiting many human cancers. In the case of non-functional p53 status, p73, the p53 homologue, may play a role in apoptosis induction.
Our results demonstrated that treatment with raloxifene significantly suppresses lymph node metastasis in a mouse mammary cancer model expressing cytoplasmic ERα. The antimetastatic activity of raloxifene may be a crucial finding with clinical applications, and raloxifene may be useful as an adjuvant therapy and for the chemoprevention of breast cancer development.
Continuing Outcomes Relevant to Evista
Results of other clinical trials of raloxifene, such as the Multiple Outcomes of Raloxifene Evaluation
mouse mammary tumor virus
reverse transcriptase-polymerase chain reaction
Raloxifene Use for The Heart
selective estrogen receptor modulator
Study of Tamoxifen and Raloxifene
terminal deoxynucleotidyl transferase-mediated dUTP-FITC nick end-labeling.
This investigation was supported by a Grant-in-Aid for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (referred to as Shibata's Project in the Central Research Laboratory of Osaka Medical College). We thank Dr. Shingo Kamoshida (Kobe University Graduate School of Health Sciences) for immunohistochemistry for caspases and Mr. Teruo Ueno (the Central Research Laboratory of Osaka Medical College) for assistance with the cell-cycle analysis. We are also grateful to Ms. Mika Yoshida and Yumi Naimita for their warm-hearted secretarial assistance.
- Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998, 90 (18): 1371-1388. 10.1093/jnci/90.18.1371.View ArticlePubMedGoogle Scholar
- Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N: Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1995, 87 (9): 645-651. 10.1093/jnci/87.9.645.View ArticlePubMedGoogle Scholar
- Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003, 361 (9354): 296-300. 10.1016/S0140-6736(03)12342-2.View ArticlePubMedGoogle Scholar
- Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science. 2002, 295 (5564): 2465-2468. 10.1126/science.1068537.View ArticlePubMedGoogle Scholar
- Clemens JA, Bennett DR, Black LJ, Jones CD: Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen induced mammary tumors and on LH and prolactin levels. Life Sci. 1983, 32 (25): 2869-2875. 10.1016/0024-3205(83)90323-5.View ArticlePubMedGoogle Scholar
- Gottardis MM, Jordan VC: Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987, 47 (15): 4020-4024.PubMedGoogle Scholar
- Anzano MA, Peer CW, Smith JM, Mullen LT, Shrader MW, Logsdon DL, Driver CL, Brown CC, Roberts AB, Sporn MB: Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9-cis-retinoic acid. J Natl Cancer Inst. 1996, 88 (2): 123-125. 10.1093/jnci/88.2.123.View ArticlePubMedGoogle Scholar
- Janakiram NB, Steele VE, Rao CV: Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res (Phila Pa). 2009, 2 (1): 52-59.View ArticleGoogle Scholar
- Vogel VG: The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009, 9 (1): 51-60. 10.1586/14737220.127.116.11.View ArticlePubMedPubMed CentralGoogle Scholar
- Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Jama. 1999, 281 (23): 2189-2197. 10.1001/jama.281.23.2189.View ArticlePubMedGoogle Scholar
- Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004, 96 (23): 1751-1761. 10.1093/jnci/djh319.View ArticlePubMedGoogle Scholar
- Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006, 355 (2): 125-137. 10.1056/NEJMoa062462.View ArticlePubMedGoogle Scholar
- Lee WL, Cheng MH, Chao HT, Wang PH: The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J Obstet Gynecol. 2008, 47 (1): 24-31. 10.1016/S1028-4559(08)60051-0.View ArticlePubMedGoogle Scholar
- Kuroishi T, Tominaga S: Epidemiol. Breast Cancer. Jpn J Cancer Chemother. 2001, 28: 168-173.Google Scholar
- Shibata MA, Morimoto J, Otsuki Y: Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther. 2002, 9: 16-27. 10.1038/sj.cgt.7700415.View ArticlePubMedGoogle Scholar
- Shibata MA, Ito Y, Morimoto J, Otsuki Y: Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis. 2004, 25: 1887-1898. 10.1093/carcin/bgh201.View ArticlePubMedGoogle Scholar
- Shibata MA, Morimoto J, Shibata E, Otsuki Y: Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther. 2008, 15 (12): 776-786. 10.1038/cgt.2008.43.View ArticlePubMedGoogle Scholar
- Shibata MA, Shibata E, Morimoto J, Eid NAS, Tanaka Y, Watanabe M, Otsuki Y: An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging. Anticancer Res. 2009, 29: 4389-4396.PubMedGoogle Scholar
- Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandy T, Korsmeyer SJ, Green JE: Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J. 1999, 18: 2692-2701. 10.1093/emboj/18.10.2692.View ArticlePubMedPubMed CentralGoogle Scholar
- Yoshimori A, Sakai J, Sunaga S, Kobayashi T, Takahashi S, Okita N, Takasawa R, Tanuma S: Structural and functional definition of the specificity of a novel caspase-3 inhibitor, Ac-DNLD-CHO. BMC Pharmacol. 2007, 7: 8-10.1186/1471-2210-7-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Tanuma S, Yoshimori A, Takasawa R: Genomic drug discovery for apoptosis regulation using a new computer screening amino acid complement wave method. Biol Pharm Bull. 2004, 27 (7): 968-973. 10.1248/bpb.27.968.View ArticlePubMedGoogle Scholar
- Shibata MA, Akao Y, Shibata E, Nozawa Y, Ito T, Mishima S, Morimoto J, Otsuki Y: Vaticanol C, a novel resveratrol tetramer, reduces lymph node and lung metastases of mouse mammary carcinoma carrying p53 mutation. Cancer Chemother Pharmacol. 2007, 60: 681-691. 10.1007/s00280-007-0414-y.View ArticlePubMedGoogle Scholar
- O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC: Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res. 2006, 12 (7 Pt 1): 2255-2263. 10.1158/1078-0432.CCR-05-2584.View ArticlePubMedGoogle Scholar
- Gorrin-Rivas MJ, Arii S, Furutani M, Mizumoto M, Mori A, Hanaki K, Maeda M, Furuyama H, Kondo Y, Imamura M: Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis. Clin Cancer Res. 2000, 6 (5): 1647-1654.PubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Lee LM, Cao J, Deng H, Chen P, Gatalica Z, Wang ZY: ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res. 2008, 28 (1B): 479-483.PubMedPubMed CentralGoogle Scholar
- Musgrove EA, Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009, 9 (9): 631-643. 10.1038/nrc2713.View ArticlePubMedGoogle Scholar
- Simoncini T, Genazzani AR, Liao JK: Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation. 2002, 105 (11): 1368-1373. 10.1161/hc1102.105267.View ArticlePubMedGoogle Scholar
- Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science. 1996, 273 (5279): 1222-1225. 10.1126/science.273.5279.1222.View ArticlePubMedGoogle Scholar
- Filardo EJ, Quinn JA, Bland KI, Frackelton AR: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol. 2000, 14 (10): 1649-1660. 10.1210/me.14.10.1649.View ArticlePubMedGoogle Scholar
- Dowsett M: Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res. 2003, 9 (1 Pt 2): 502S-510S.PubMedGoogle Scholar
- Chi A, Chen X, Chirala M, Younes M: Differential expression of estrogen receptor beta isoforms in human breast cancer tissue. Anticancer Res. 2003, 23 (1A): 211-216.PubMedGoogle Scholar
- Cammarata PR, Chu S, Moor A, Wang Z, Yang SH, Simpkins JW: Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res. 2004, 78 (4): 861-871. 10.1016/j.exer.2003.09.027.View ArticlePubMedGoogle Scholar
- Hengartner MO: The biochemistry of apoptosis. Nature. 2000, 407: 770-776. 10.1038/35037710.View ArticlePubMedGoogle Scholar
- Finlay D, Vuori K: Novel noncatalytic role for caspase-8 in promoting SRC-mediated adhesion and Erk signaling in neuroblastoma cells. Cancer Res. 2007, 67 (24): 11704-11711. 10.1158/0008-5472.CAN-07-1906.View ArticlePubMedGoogle Scholar
- Yao Z, Duan S, Hou D, Heese K, Wu M: Death effector domain DEDa, a self-cleaved product of caspase-8/Mch5, translocates to the nucleus by binding to ERK1/2 and upregulates procaspase-8 expression via a p53-dependent mechanism. Embo J. 2007, 26 (4): 1068-1080. 10.1038/sj.emboj.7601571.View ArticlePubMedPubMed CentralGoogle Scholar
- Morishima N, Nakanishi K, Takenouchi H, Shibata T, Yasuhiko Y: An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem. 2002, 277 (37): 34287-34294. 10.1074/jbc.M204973200.View ArticlePubMedGoogle Scholar
- Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C: A controlled trial of raloxifene (LY139411681) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res. 1996, 835-842.Google Scholar
- Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW: Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol. 1997, 177 (6): 1458-1464. 10.1016/S0002-9378(97)70091-7.View ArticlePubMedGoogle Scholar
- Flamini MI, Fu XD, Sanchez AM, Giretti MS, Garibaldi S, Goglia L, Pisaneschi S, Tosi V, Genazzani AR, Simoncini T: Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med. 2009, 13 (8B): 2396-2407. 10.1111/j.1582-4934.2008.00505.x.View ArticlePubMedGoogle Scholar
- Esposito E, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, Meli R: Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology. 2005, 146 (8): 3301-3308. 10.1210/en.2005-0375.View ArticlePubMedGoogle Scholar
- Folkman J: Angiogenesis-dependent diseases. Semin Oncol. 2001, 28 (6): 536-542. 10.1016/S0093-7754(01)90021-1.View ArticlePubMedGoogle Scholar
- Doshida M, Ohmichi M, Tsutsumi S, Kawagoe J, Takahashi T, Du B, Mori-Abe A, Ohta T, Saitoh-Sekiguchi M, Takahashi K, et al: Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells. J Biol Chem. 2006, 281 (34): 24270-24278. 10.1074/jbc.M513251200.View ArticlePubMedGoogle Scholar
- Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994, 54: 4855-4878.PubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/566/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.